Penetrium Bioscience Tests New Combination Cancer Treatment with Merck’s Keytruda

Penetrium Bioscience tests new combination cancer treatment with Merck’s Keytruda

South Korea's Penetrium Bioscience said Wednesday that the company would start a clinical test combining its investigational cancer drug Penetrium with Merck's immunotherapy Keytruda.

Penetrium Bio launches trial combining new cancer drug with Merck’s Keytruda

Pictured above is the logo of Penetrium Bioscience. [Photo courtesy of Penetrium Bioscience] South Korea’s Penetrium Bioscience announced on June 17 that it has launched a Phase 1 clinical trial combining its investigational cancer drug Penetrium with Merck’s blockbuster immunotherapy Keytruda. The company said that the trial will enroll patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) who have failed pre…